Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
CONCLUSIONS: Pembrolizumab has to be recommended in second-line therapy due to reporting in a phase III trial and OS survival benefit compared to chemotherapy control group. In cisplatin-eligible and treatment-naïve patients with visceral or liver metastases data also slightly favors pembrolizumab rather than atezolizumab.
PMID: 30021426 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Study | Urology & Nephrology